Advertisement
Advertisement

Hepatitis C Virus (HCV) and HIV/HCV Coinfection: A Critical Review of Research and Treatment

Appendix A: Chart of Drugs in Development

July 2004

Drug ClassDeveloperCompoundStage
HCV NS3 serine protease inhibitorsBoehringer IngelheimBILN 2061Completed phase I; planned phase II on hold pending investigation of toxicities in animals
VertexVX-950Phase I to begin in 2004
Schering-PloughSCH7Phase I
HCV NS5B RNA-dependent RNA polymerase inhibitorsIdenixNM283Phase II in combination with pegylated interferon to begin in 2004
Japan TobaccoJTK-003Phase II
Japan TobaccoJTK-109Phase I
RigelR803Phase I/II
RocheR1479Phase I
ViroPharmaHCV-086Phase I
Imino sugar derivativesMicrologixMBI-2353 (celgosivir)Phase II to begin in 2004
United TheraputicsUT231BPhase II
Monoclonal antibodiesXTLHepeX-CPhase II
Antisense oligonucleotidesIsisISIS-14803Phase I/II in combination with pegylated interferon and ribavirin
Interferon variants and alternatesInterMuneInfergen (interferon alfacon-1; consensus interferon)Phase III study in combination with ribavirin initiated in 2004
InterMunepegylated InfergenPhase I conducted in 2003, further development on hold for financial reasons
Human Genome SciencesAlbuferon-alphaPhase II dose-ranging study underway
BioMedicinesomega interferonPhase II underway
InterMuneinterferon gamma-1b (Actimmune)Phase II study in combination with Infergen initiated in 2004
Next-generation ribavirinValeantViramidine (ribavirin prodrug)Phase III studies in combination with pegylated interferon
VertexMerimepodib (Vertex 497, an IMPDH inhibitor)Phase IIb study in combination with pegylated interferon and ribavirin to begin in 20004
Other immunomodulators, broad antivirals, and non-specific therapiesSciCloneZadaxin (thymosin alfa-1; thymlfasin)Two phase III studies in combination with pegylated interferon; another phase III study in combination with pegylated interferon and ribavirin to begin in 2004
MaximCeplene (histamine dihydrochloride)Phase II study with pegylated interferon and ribavirin; phase Ia study of oral formulation completed
Anadysisatoribine (ANA 245, a TLR7 agonist)Phase I; ANA 971 (an oral prodrug of isatoribine) entered phased I in 2004
ColeyActilon (CPG 10101, a TLR9 agonist)Phase I/II underway; phase II to begin in 2004
Kemin PharmaKPE02003002Phase II
IdunIDN-6556 (apoptosis inhibitor)Phase II planned
VaccinesInnogeneticstherapeutic vaccinePhase II
Intercelltherapeutic vaccinePhase II
Chirontherapeutic vaccinePhase I
Chironpreventative vaccinePhase I





This article was provided by Treatment Action Group.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.